ArticleBMC complementary medicine and therapies2025
In vitro antibacterial activity of Moringa oleifera leaf and seed extracts against antibiotic-resistant bacteria and clinical isolates.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genome-guided discovery of antibiotic activity iniScience · 2026Article
- Comparative analysis of antibacterial and antioxidant properties as well as phytochemical compositions of Moringa oleifera gum, flower, and fruit and Elaeocarpus augustifolius leaf and bark, synergistic with Pleurotus membranaceus.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResistance to antibiotic has increased extensively over the years, posing a serious threat to public health. Plants are promising sources of antibiotic-resistance inhibitors. The aim of this study is to investigate the antibacterial properties leaf and seed extracts of Moringa oleifera against strains of pathogenic bacteria.
methodsEight extracts of M. oleifera leaves and seeds were prepared using four solvents; water, ethanol, ethyl acetate and petroleum ether, and evaluated against drug-resistant clinical isolates and standard laboratory strains of Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa using disc diffusion method. Minimum inhibitory concentration of the extracts was determined by broth microdilution method.
resultsThe results show that aqueous extracts of both leaves and seeds had higher zones of inhibition for all the isolates, including Methicillin-resistant S. aureus, E. coli ESBL, meropenem-resistant E. coli, than the rest of the extracts, with zones of inhibition ranging from 20.0 mm to 32.5 mm. Ethyl acetate seed extract also inhibited all the isolates except Meropenem-resistant E. coli. Likewise, ethyl acetate leaf extract inhibited all except the E. coli isolates and had significantly higher zones inhibition for almost all the isolates compared to the ethyl acetate seed extract. However, aqueous seed extract showed the lowest minimum inhibitory concentration against all bacteria strains, ranging from 50 mg/ml to 200 mg/ml.
conclusionsThe data indicates that aqueous and ethyl acetate extracts of M. oleifera, particularly aqueous seed extract, have the potential of capturing inhibitors against drug-resistant and clinical isolates of S. aureus, P. aeruginosa and E. coli.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.